$22.71
3.13% yesterday
Nasdaq, Dec 03, 10:00 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$22.71
-1.07 4.50% 1M
+7.27 47.09% 6M
-2.06 8.32% YTD
-5.51 19.53% 1Y
+8.35 58.15% 3Y
-27.61 54.87% 5Y
+12.76 128.24% 10Y
+12.76 128.24% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.69 3.13%
ISIN
US45258J1025
Symbol
IMVT
Industry

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.5b
Net debt
positive
Cash
$521.9m
Shares outstanding
174.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
7.7
Financial Health
Equity Ratio
91.1%
Return on Equity
-58.5%
ROCE
-93.7%
ROIC
-919.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-486.4m | $-533.9m
EBIT
$-486.8m | $-546.6m
Net Income
$-464.6m | $-522.0m
Free Cash Flow
$-431.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-38.1% | -22.0%
EBIT
-38.1% | -24.7%
Net Income
-43.9% | -26.1%
Free Cash Flow
-58.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
$-2.5
Short interest
27.0%
Employees
207
Rev per Employee
$0.0
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

17x Buy
74%
6x Hold
26%

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

Buy
74%
Hold
26%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
29% 29%
-
- Research and Development Expense 404 404
41% 41%
-
-486 -486
38% 38%
-
- Depreciation and Amortization 0.42 0.42
45% 45%
-
EBIT (Operating Income) EBIT -487 -487
38% 38%
-
Net Profit -465 -465
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
Seeking Alpha
24 days ago
Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Neutral
GlobeNewsWire
24 days ago
Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren's disea...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Eric Venker
Employees 207
Founded 2018
Website immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today